Samsung Bioepis said on the 2nd that it carried out a range of activities to mark its 14th anniversary.
On Feb. 27, the company held a commemorative event at its Songdo office in Incheon, presented awards to outstanding employees and departments, and planted an apricot tree symbolizing a new beginning.
To mark "Rare Disease Day" (Feb. 28), it carried out a variety of community contribution activities with the nongovernmental organization (NGO) Save the Children, including fundraising for children with rare diseases, distributing goods, making donations, assembling first-aid kits, and writing support cards.
Samsung Bioepis currently supplies a total of 11 biosimilar products in Korea, including "EPYSQLI (EPYSQLI®)," a treatment for rare diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica spectrum disorder (NMOSD).
EPYSQLI is a biosimilar of Soliris and was launched in Korea in Apr. 2024 at about half the price of the original drug.
The company said it aims to improve patient access to ultra-high-priced rare disease treatments through this and help reduce health insurance spending.
President Kim Kyung-ah of Samsung Bioepis said, "Based on the achievements and passion we have built over the past 14 years to improve patients' quality of life through high-quality biopharmaceuticals, we will continue to grow as a corporation respected by society."
Samsung Bioepis, founded in Feb. 2012, posted annual sales of 1.672 trillion won in 2025, achieving its best performance ever. Under Samsung Epis Holdings, an investment holding company established in Nov. last year, the company is expanding its biosimilar pipeline while also actively pursuing new drug development focused on antibody-drug conjugates (ADC).